OBIEDO, PATRICIA JOY L.

BSN II-B
1
Bacillus Calmette Guerin
Percutaneous dosage

Adults, Adolescents, Children, and Infants >= 1 month

0.2 to 0.3 mL is dropped on the skin and administered
using a multiple puncture disc

Neonates < 1 month

The BCG Vaccine, should be reconstituted with 2 mL
for these patients to administer the appropriate
dose, which is 50% of the adult dose. Then, 0.2 to
0.3 mL of the diluted solution is dropped on the skin
and administered using a multiple puncture disc
 For tuberculosis prophylaxis in
patients who have not been previously
infected with Mycobacterium
tuberculosis but who are at high risk of
exposure.
Pregnancy
The manufacturer recommends against use of
the BCG vaccine during pregnancy

Breast-feeding
Data are limited regarding use of the Bacillus
Calmette-Guerin (BCG) vaccine during breast-
feeding and its' excretion in breast milk is
unknown. The manufacturer recommends
deciding between discontinuing nursing or
avoiding vaccination
 Bacillus Calmette-Guerin (BCG) is an
immunostimulant that is used to stimulate the
immune system to produce immunity against
tuberculosis.
 Antimicrobial or
immunosuppressive agents may
interfere with the development of the
immune response and should be
used only under medical supervision.
Severe
erythema nodosum, lupus-like symptoms,
erythema
Moderate
skin ulcer, lymphadenopath, erythema
Mild
Arthralgia, myalgia , infection, anorexia, fever,
injection site reaction, urticaria, rash
Before administration of BCG Vaccine, health
care personnel should inform patients or
guardians of the benefits and risks of
immunization and inquire about the health
status of the patient
BCG vaccine contains live bacteria and
should be used with aseptic technique
Administration should be by the percutaneous
route
2
Hepatitis B Vaccine

ADD YOUR COMPANY SLOGAN

Intramuscular dosage

Infants, Children, and Adolescents

0.06 mL/kg/dose IM as soon as possible after
exposure (preferably less than 24 hours after
exposure but no later than 7 days after exposure)
plus hepatitis B vaccination series initiation or
completion at a different site.
Neonates born to HBsAg-positive mothers and neonates
less than 2 kg† born to mothers with unknown HBsAg
status
0.5 mL IM for 1 dose after physiologic
stabilization of the infant and preferably within 12
hours of birth plus hepatitis B vaccination series
initiation at a different site
Neonates and Infants whose primary caregiver has
acute HBV infection
0.5 mL IM for 1 dose as soon as possible after
exposure plus hepatitis B vaccination series
initiation or completion at a different site
For post-exposure hepatitis B
prophylaxis
Perinatal exposure
Household exposure to persons with
acute HBV infection
Neonates, premature neonates

Pregnancy

Breast-feeding
 This vaccine works by helping the
body produce immunity (through antibody
production) that will prevent you from
getting infection from hepatitis B virus
Hepatitis B Immune Globulin, HBIG: Administration of
hepatitis B virus vaccines (e.g., hepatitis B vaccine,
recombinant) at the same site or in the same syringe
as hepatitis B immune globulin, HBIG can result in
neutralization.
Ocrelizumab: May interfere with the effectiveness of
non-live virus vaccines.
Siponimod: Vaccines may be less effective if given
during siponimod treatment and for 1 month after
discontinuation of siponimod treatment.
Moderate
Erythema, hypotension

Mild
Headache, injection site reaction, myalgia,
malaise, nausea, arthralgia, ecchymosis,
vomiting, tremor, urticaria, chills, fatigue,
diarrhea, back pain, dizziness, syncope, fever,
infection
 Be aware of maternal hepatitis status at
appropriate ages
 Notify physician of need for vaccine
 Draw back on the plunger of the syringe
before injection to avoid intravascular
injection
Thanks for your time and attention!